These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26846675)

  • 1. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study.
    Descombes E; Martins F; Hemett OM; Erard V; Chuard C
    BMC Pharmacol Toxicol; 2016 Feb; 17():4. PubMed ID: 26846675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
    Georges B; Conil JM; Cougot P; Decun JF; Archambaud M; Seguin T; Chabanon G; Virenque C; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):360-9. PubMed ID: 16119511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem.
    Tanaka A; Takechi K; Watanabe S; Tanaka M; Suemaru K; Araki H
    Int J Clin Pharm; 2013 Oct; 35(5):683-7. PubMed ID: 23733559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective monitoring of cefepime in intensive care unit adult patients.
    Chapuis TM; Giannoni E; Majcherczyk PA; Chioléro R; Schaller MD; Berger MM; Bolay S; Décosterd LA; Bugnon D; Moreillon P
    Crit Care; 2010; 14(2):R51. PubMed ID: 20359352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study.
    Huwyler T; Lenggenhager L; Abbas M; Ing Lorenzini K; Hughes S; Huttner B; Karmime A; Uçkay I; von Dach E; Lescuyer P; Harbarth S; Huttner A
    Clin Microbiol Infect; 2017 Jul; 23(7):454-459. PubMed ID: 28111294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study.
    Alves MD; Ribeiro VB; Tessari JP; Mattiello F; De Bacco G; Luz DI; Vieira FJ; Behle TF; Pasqualotto AC; Zavascki AP
    J Antimicrob Chemother; 2014 Jun; 69(6):1681-7. PubMed ID: 24474430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefepime dosing in the morbidly obese patient population.
    Rich BS; Keel R; Ho VP; Turbendian H; Afaneh CI; Dakin GF; Pomp A; Nicolau DP; Barie PS
    Obes Surg; 2012 Mar; 22(3):465-71. PubMed ID: 22249886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
    Fernandez J; Hilliard JJ; Abbanat D; Zhang W; Melton JL; Santoro CM; Flamm RK; Bush K
    Antimicrob Agents Chemother; 2010 Jan; 54(1):116-25. PubMed ID: 19884364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC.
    Rhodes NJ; Liu J; McLaughlin MM; Qi C; Scheetz MH
    Diagn Microbiol Infect Dis; 2015 Jun; 82(2):165-71. PubMed ID: 25801780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
    Jaruratanasirikul S; Sriwiriyajan S; Ingviya N
    J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes.
    Schmaldienst S; Traunmüller F; Burgmann H; Rosenkranz AR; Thalhammer-Scherrer R; Hörl WH; Thalhammer F
    Eur J Clin Pharmacol; 2000 Apr; 56(1):61-4. PubMed ID: 10853879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefazolin in chronic hemodialysis patients: a safe, effective alternative to vancomycin.
    Fogel MA; Nussbaum PB; Feintzeig ID; Hunt WA; Gavin JP; Kim RC
    Am J Kidney Dis; 1998 Sep; 32(3):401-9. PubMed ID: 9740155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.
    Rhodes NJ; Kuti JL; Nicolau DP; Van Wart S; Nicasio AM; Liu J; Lee BJ; Neely MN; Scheetz MH
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1401-10. PubMed ID: 26666929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of cefepime in a Staphylococcus aureus endocarditis rat model.
    Lamb LM; Hibbard JR; Desiderio JV; Tsai YH
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():95-101. PubMed ID: 8150772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.